Pfizer’s sasanlimab combo significantly improves event-free survival in BCG-naïve, high-risk non-muscle invasive bladder ...
Pfizer Inc. announced results from the pivotal phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without …